Morning Chronicle - News from London and the UK, around the clock in six languages

London -

IN THE NEWS

What is the status of US tariff negotiations?

What is the status of US tariff negotiations?

US tariff negotiations with key trading partners have shifted into high gear as economies race to avoid steeper duties before an August 1 deadline.

Read more
State of play in Trump's tariffs, threats and delays

State of play in Trump's tariffs, threats and delays

Dozens of economies including India, Canada and Mexico face threats of higher tariffs Friday if they fail to strike deals with Washington.

Read more
UN tackles beleaguered two-state solution for Israel, Palestinians

UN tackles beleaguered two-state solution for Israel, Palestinians

France and Saudi Arabia will lead the charge starting Monday to revive the moribund push for a two-state solution between Israel and the Palestinians at a UN conference in New York.

Read more
Wallabies call up former All Black prop Ross for third Lions Test

Wallabies call up former All Black prop Ross for third Lions Test

Australia on Monday called up former All Blacks prop Aidan Ross for the third and final Test against the British and Irish Lions, while wing Harry Potter was ruled out injured.

Read more
Australia rugby boss seeks answers on controversial Lions try

Australia rugby boss seeks answers on controversial Lions try

Australian rugby boss Phil Waugh has demanded World Rugby explain a controversial decision by the referee to award the British and Irish Lions a series-clinching try in the second Test.

Read more
Monfils says Toronto loss marks his final Toronto visit

Monfils says Toronto loss marks his final Toronto visit

Gael Monfils said he has played for the last time in Toronto after crashing out of the Masters in Sunday's opening round of the ATP Masters to a Chilean qualifier.

Read more
GoodData Powers the Next Wave of BI With Intelligent Data Automation

GoodData Powers the Next Wave of BI With Intelligent Data Automation

Deliver intelligent data workflows that automatically schedule exports, trigger alerts, and deliver insights when and where they matter.

Read more
EverC and AWS - Collaborating on GenAI technology

EverC and AWS - Collaborating on GenAI technology

NEW YORK CITY, NY / ACCESS Newswire / July 28, 2025 / Since Q4 2024, EverC, a leading provider of AI-driven risk management solutions for digital commerce, has been working with Amazon Web Services (AWS) to support innovation.

Read more
Providence Film Group Launches "Last Voice" with Record-Breaking $51M Budget - Poised to Become Highest-Budget African American Indie Film Ever

Providence Film Group Launches "Last Voice" with Record-Breaking $51M Budget - Poised to Become Highest-Budget African American Indie Film Ever

LOS ANGELES, CA / ACCESS Newswire / July 28, 2025 / Providence Film Group, a subsidiary of Valiant Eagle Inc. (OTC PINK:PSRU), proudly announces the official development and full financing of Last Voice (working title), an epic historical drama inspired by the story of Bilal ibn Rabah (may Allah be pleased with him)- and now set to become the highest-budget African American independent film in history. "This isn't just a film - it's a historic achievement for Black Hollywood," said Dr. Xavier "X" Mitchell, writer and producer. "We are demonstrating that African American-led stories deserve epic scale, major investment, and a global audience. With a groundbreaking $51 million budget, Last Voice surpasses previous milestones set by films such as "The Woman King," establishing a new standard for representation, scale, and ambition in Hollywood.

Read more
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases

GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable pharmacokinetic profile and high brain penetration. These findings support the advancement of SUL-238 into further clinical development for Alzheimer's and other neurodegenerative diseases.

Read more